



## Curriculum Vitae

Personal information **Anita Wolfer**

### Work experience

---

08/2022	Senior Clinical Assessor, Unit Haematology and Oncology, Division Clinical Assessment, Department of Authorisations, Swissmedic, Bern, Switzerland
5/2022-7/2022	Chief scientific officer at SAKK (Swiss Working Group for Clinical Oncology Trials), Bern, Switzerland
2/2021-4/2022	Senior Clinical Assessor, Unit Haematology and Oncology, Department of Authorisations, Swissmedic
6/2020-1/2021	Clinical Assessor, deputy Unit Head Haematology and Oncology, Department of Authorisations, Swissmedic
1/2019-5/2020	Clinical Assessor, Unit Haematology and Oncology, Department of Authorisations, Swissmedic
9/2017-12/2018	Médecin associée, medical oncology (gynaecologic oncology) and immuno-oncology, Department of Oncology, University Hospital of Lausanne (CHUV), Switzerland
1/2013-8/2017	Cheffe de clinique in medical oncology (breast cancer and gynaecological malignancies), Department of Oncology, University Hospital of Lausanne (CHUV), Switzerland
1/2012-12/2012	Cheffe de Clinique in medical oncology, Centre Pluridisciplinaire d'Oncologie, University Hospital of Lausanne, Switzerland
9/2010-12/2011	Research and clinical fellow in medical oncology, Centre Pluridisciplinaire d'Oncologie, University Hospital of Lausanne, Switzerland
10/2006-7/2010	Research fellow, Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, USA
4/2005-9/2006	Clinical fellow in medical oncology, Centre Pluridisciplinaire d'Oncologie, University Hospital of Lausanne, Switzerland
4/2004-3/2005	Clinical Fellow, internal medicine, University Hospital of Lausanne, Switzerland
4/2003-3/2004	Resident, medical oncology, Centre Pluridisciplinaire d'Oncologie, University Hospital of Lausanne, Switzerland
4/2002-03/2003	Intern, internal medicine, University Hospital of Lausanne, Switzerland

### Education and training

---

2/2012	<i>Foederatio Medicorum Helveticorum</i> (FMH) in Medical Oncology (specialist title)
--------	---

5/2002 M.D.-Ph.D., Swiss Academy of Medical Sciences,  
University of Lausanne, Switzerland  
12/1998 Swiss Federal Diploma of Medicine, University of  
Lausanne, Switzerland

## Additional information

---

### Publications

#### *Original articles*

- U-P. Rohr<sup>+</sup>, M. Iovino<sup>+</sup>; L. Rudofsky, Q. Li, S. Juritz, A. Gircys, O. Wildner, M. Bujar, C. Bolte, S. Dalla-Torre di Sanguinetto<sup>+</sup>, A. Wolfer<sup>+</sup>. 2023. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration. **Clin Transl Sci**. 2023;00:1–13. (<sup>+</sup>equal contributions)
- S. Anchisi, A. Wolfer, B. Bisig, E. Missiglia, A. Tiab, EM. Kamel, O. Michielin, G. Coukos, K. Homicsko. 2022. Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient. **Cancer Biol Ther**. 2022 Dec 31;24(1):2193116.
- SI. Labidi-Galy, T. de La Motte Rouge, O. Derbel, A. Wolfer, E. Kalbacher, T. Olivier, JD. Combes, K. Heimgartner-Hu, O. Tredan, H. Guevara, PE. Heudel, T. Reverdy, F. Bazan, V. Heinzelmann-Schwarz, M. Fehr, V. de Castelbajac, P. Vaflard, L. Crivelli, V. Bonadona, V. Viassolo, A. Buisson, L. Golmard, M. Rodrigues, I. Ray-Coquard. 2019. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. **Gynecol Oncol**. 2019 Nov;155(2):262-269.
- F. Schyrr, A. Wolfer, J. Pasquier, AL. Nicoulaz, O. Lamy, O. Naveiras. 2018. Correlation study between osteoporosis and hematopoiesis in the context of adjuvant chemotherapy for breast cancer. **Ann Hematol**. 2018; 97(2):309-317.
- F. Grass, D. Martin, M. Montemurro, P. Mathevet, A. Wolfer, G. Coukos, N. Demartines, M. Hübner. 2018. Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network. **Chemotherapy**. 2018;63(3):143-147.
- M. Hübner, H. Teixeira Farinha, F. Grass, A. Wolfer, P. Mathevet, D. Hahnloser, Demartines N. 2017. Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study. **Gastroenterol Res Pract**. 2017:6852749.
- X. Pivot, F. Marmé, R. Koenigsberg, M. Guo, E. Berrak, A. Wolfer. 2016. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. **Ann. Oncol**. 27(8):1525-31.
- S. Zimmermann, K. Zaman, A. Wolfer, W. Jacot. 2012. Severe peritonitis induced by methotrexate during treatment of persistent gestational trophoblastic disease. **Oncologist** 17(8):e18-20.
- I. Dey-Guha\*, A. Wolfer\*, A. C. Yeh, J. G. Albeck, R. Darp, E. Leon, J. Wulfkuhle, E. F. Petricoin, B. S. Wittner, S. Ramaswamy. 2011. Asymmetric cancer cell division regulated by AKT. **Proc. Natl. Acad. Sci. U. S. A.** 108:12845-50. (\*equal contribution)
- A. Wolfer\*, B. S. Wittner\*, D. Irimia, R. J. Flavin, M. Lupien, R. N.

- Gunawardane, C. A. Meyer, E. S. Lightcap, P. Tamayo, J. P. Mesirov, X. S. Liu, T. Shioda, M. Toner, M. Loda, M. Brown, J. S. Brugge, S. Ramaswamy. 2010. MYC regulation of a “poor-prognosis” metastatic human cancer cell state. **Proc. Natl. Acad. Sci. U. S. A.** 107:3698-703. (\*equal contribution)
- M. Nicolas, A. Wolfer, K. Raj, J.A. Kummer, P. Mill, M. van Noort, C. C. Hui, H. Clevers, G. P. Dotto, F. Radtke. 2003. Notch1 functions as a tumor suppressor in mouse skin. **Nat. Genet.** 33:416-21.
- A. Wolfer\*, A. Wilson\*, M. Nemir, H. R. MacDonald and F. Radtke. 2002. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta lineage thymocytes. **Immunity** 16:869-79. (\*equal contribution)
- A. Wolfer, T. Bakker, A. Wilson, M. Nicolas, V. Ioannidis, D. R. Litman, C. B. Wilson, P. P. Lee, C. B. Wilson, W. Held, H. R. MacDonald and F. Radtke. 2001. Inactivation of Notch1 in immature thymocytes does not perturb CD4 or CD8 T cell development. **Nat. Immunol.** 2:235-41.  
Commentary: Rothenberg, E. V. 2001. Notchless T cell maturation? **Nat. Immunol.** 2:189-90.

#### *Meeting abstracts*

- \*S. Banerjee, P. B. Ottevanger, A. Sarivalasis, R. Le Scodan, A. Montes, J. R. Kroep, M. Romeo Marin, A. Casado Herraez, M. Auvray-Kuentz, A. M. Westermann, B. Lucas, D. Dangaj, F. Herrera, A. Wolfer, C. Coens, M. B. Vanlancker, L. Kandalajt, G. Coukos. 2021. Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma. **Ann. Oncol.** 32(Suppl. 5):S1308-S1308 (Meeting Abstract LBA32).
- \*R.E. O’Cearbhaill, K. Homicsko, A. Wolfer, P.A. Di Silvestro, D.M. O’Malley, P. Sabbatini, A. Orcurto, D. Barras, L. Shohara, T. Ricciardi, M. Macri, A. Ryan, R.R. Venhaus, B.J. Monk. G. Coukos. 2020. A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results. **Gynecol Oncol.** 159 (suppl. 1): 41.
- Y.Drew, M.de Jonge, S.H.Hong, Y.H.Park, A.Wolfer, J.Brown, M.Ferguson, M.E.Gore, R.H.Alvarez, C.Gresty, H.Angell, K.Meyer, M.Learoyd, M.Tang, M.Lanasa, P.Herbolsheimer, S.M.Domchek. 2018. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). **Gynecol Oncol.** 149 (suppl. 1): 246-247.
- \*R.E. O’Cearbhaill, A. Wolfer, P. Disilvestro, D.M. O’Malley, P. Sabbatini, L. Shohara, P.O. Schwarzenberger, T. Ricciardi, M. Macri, A. Ryan, R.R. Venhaus, J.K. Bryan, P. Wong, K. Homicsko, L. Kandalajt, S. Rusakiewicz, A. Harari, B.J. Monk, G. Coukos. 2018. A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). **Ann. Oncol.** 29 (suppl. 8): viii337.

#### *Review articles*

- S. Martin Lluesma, A. Wolfer, A. Harari, L. Kandalajt. 2016. Cancer Vaccines in Ovarian Cancer: How Can We Improve? **Biomedicines**. 4(2):10.
- S. Guiu, A. Wolfer, W. Jacot, P. Fumoleau, G. Romieu, F. Bonnetain, M. Fiche. 2014. Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions? **Crit Rev Oncol Hematol**. 92(3):235-57.
- W. Jacot, M. Fiche, K. Zaman, A. Wolfer, P.J. Lamy. 2013. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. **BBA Rev Cancer**. 1836: 146-57.
- A. Wolfer and S. Ramaswamy. 2011. MYC and metastasis. **Cancer Res**. 71:2034-7.
- A. Wolfer and S. Ramaswamy. 2010. Prognostic signatures, cancer metastasis, and MYC. **Cell Cycle**. 9:3639

Projects

Memberships

1998	Swiss Medical Society, FMH, full member
2011	European Society of Medical Oncology, full member
2011	American Association for Cancer Research, associate member
2014	Swiss Society of Medical Oncology, full member

Other Relevant Information